Essential Tremor Clinical Trial
Official title:
Multicenter Study of Safety and Effectiveness of Cala ONE Device for Essential Tremor
NCT number | NCT02629614 |
Other study ID # | ET-03 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2016 |
Est. completion date | November 2016 |
Verified date | June 2023 |
Source | Cala Health, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the safety and effectiveness of the Cala ONE device to aid in the symptomatic relief of hand tremors in adult essential tremor subjects. This study is a prospective, randomized, double-blinded, sham-controlled study.
Status | Completed |
Enrollment | 93 |
Est. completion date | November 2016 |
Est. primary completion date | November 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: 1. 22 years or older 2. A diagnosis of essential tremor as confirmed from clinical history and examination by a movement disorder neurologist 3. Signed informed consent 4. At least one hand exhibiting kinetic tremor = 2 as assessed by the TETRAS Archimedes spiral task completed during the baseline evaluation, as assessed by the Investigator in-person. 5. Score of 3 or above in any one of the items of the Bain & Findley ADL Scale Exclusion Criteria: 1. Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator 2. Previous thalamotomy procedure, including Stereotactic Thalamotomy, Gamma Knife Radiosurgical Thalamotomy, and focused ultrasound, for the treatment of tremor 3. Suspected or diagnosed epilepsy or other seizure disorder 4. Pregnant 5. Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site 6. Peripheral neuropathy affecting the tested upper extremity 7. Alcoholism (score of 4 or higher on DSM-5) 8. Other possible causes of tremor, including Parkinson's disease, drug-induced, enhanced physiological tremor, dystonia 9. Other neurodegenerative disease like Parkinson-plus syndromes suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and cortical basal ganglionic degeneration 10. Changes in medication for tremor within 1 month prior to study enrollment 11. Change in antidepressant medication within 3 months prior to study enrollment 12. Botulinum Toxin injection for hand tremor within 6 months prior to study enrollment 13. Current participation in any other interventional research study 14. Previous participation in any other Cala Health interventional research study 15. Alcohol or caffeine consumption within 12 hours of study enrollment Subjects already taking medications for their essential tremor will remain on their medications during the study with no changes in medication type or dosage levels. |
Country | Name | City | State |
---|---|---|---|
United States | Kansas University Medical Center | Kansas City | Kansas |
United States | UCSF | San Francisco | California |
United States | Swedish Medical Center Seattle | Seattle | Washington |
United States | The Parkinson's Institute | Sunnyvale | California |
Lead Sponsor | Collaborator |
---|---|
Cala Health, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Kinetic Tremor | The change in tremor severity on the kinetic tremor task as assessed by an investigator using the TETRAS rating scale.
The Essential Tremor Rating Assessment Scale (TETRAS) is a commonly used scale to assess and measure the severity of essential tremor. Each task was calculated individually on a 0-4 scale, with higher scores indicating more severe tremors. |
Immediately before and after 40 minute stimulation session | |
Other | Change in Kinetic Tremor | The change in tremor severity on the kinetic tremor task as assessed by an investigator using the TETRAS rating scale.
The Essential Tremor Rating Assessment Scale (TETRAS) is a commonly used scale to assess and measure the severity of essential tremor. Each task was calculated individually on a 0-4 scale, with higher scores indicating more severe tremors. |
Immediately before and 30 minutes into stimulation session | |
Other | Change in Lateral "Wing Beating" Postural Tremor | The change in tremor severity in the lateral "wing beating" postural tremor task as assessed by an investigator using the TETRAS rating scale.
The Essential Tremor Rating Assessment Scale (TETRAS) is a commonly used scale to assess and measure the severity of essential tremor. Each task was calculated individually on a 0-4 scale, with higher scores indicating more severe tremors. |
Immediately before and after 40 minute stimulation session | |
Other | Change in Lateral "Wing Beating" Postural Tremor | The change in tremor severity in the lateral "wing beating" postural tremor task as assessed by an investigator using the TETRAS rating scale.
The Essential Tremor Rating Assessment Scale (TETRAS) is a commonly used scale to assess and measure the severity of essential tremor. Each task was calculated individually on a 0-4 scale, with higher scores indicating more severe tremors. |
Immediately before and 30 minutes into stimulation session | |
Other | Change in Forward Outstretched Postural Tremor | The change in tremor severity on outstretched tremor task as assessed by an investigator using the TETRAS rating scale.
The Essential Tremor Rating Assessment Scale (TETRAS) is a commonly used scale to assess and measure the severity of essential tremor. Each task was calculated individually on a 0-4 scale, with higher scores indicating more severe tremors. |
Immediately before and after 40 minute stimulation session | |
Other | Change in Forward Outstretched Postural Tremor | The change in tremor severity on outstretched tremor task as assessed by an investigator using the TETRAS rating scale.
The Essential Tremor Rating Assessment Scale (TETRAS) is a commonly used scale to assess and measure the severity of essential tremor. Each task was calculated individually on a 0-4 scale, with higher scores indicating more severe tremors. |
Immediately before and 30 minutes into stimulation session | |
Other | Change in Bain & Findley ADL: Use a Spoon to Drink Liquid | The change in tremor severity on drinking liquid with a spoon as assessed by the subject using the Bain & Findley ADL rating scale.
The Bain and Findley Activities of Daily Living (BF-ADL) assessment evaluates the subject's ability to perform a number of specific ADLs, measured before and after treatment. Each ADL is performed by the subject and self-rated on a scale of 1-4, with higher scores indicating greater difficulty in performing the task. |
Immediately before and after 40 minute stimulation session | |
Other | Change in Bain & Findley ADL: Hold a Cup of Liquid | The change in tremor severity on holding a cup of liquid as assessed by the subject using the Bain & Findley ADL rating scale.
The Bain and Findley Activities of Daily Living (BF-ADL) assessment evaluates the subject's ability to perform a number of specific ADLs, measured before and after treatment. Each ADL is performed by the subject and self-rated on a scale of 1-4, with higher scores indicating greater difficulty in performing the task. |
Immediately before and after 40 minute stimulation session | |
Other | Change in Bain & Findley ADL: Pouring | The change in tremor severity on pouring as assessed by the subject using the Bain & Findley ADL rating scale.
The Bain and Findley Activities of Daily Living (BF-ADL) assessment evaluates the subject's ability to perform a number of specific ADLs, measured before and after treatment. Each ADL is performed by the subject and self-rated on a scale of 1-4, with higher scores indicating greater difficulty in performing the task. |
Immediately before and after 40 minute stimulation session | |
Other | Change in Bain & Findley ADL: Dialing | The change in tremor severity on dialing a telephone as assessed by the subject using the Bain & Findley ADL rating scale.
The Bain and Findley Activities of Daily Living (BF-ADL) assessment evaluates the subject's ability to perform a number of specific ADLs, measured before and after treatment. Each ADL is performed by the subject and self-rated on a scale of 1-4, with higher scores indicating greater difficulty in performing the task. |
Immediately before and after 40 minute stimulation session | |
Other | Change in Bain & Findley ADL: Picking up Change | The change in tremor severity on picking up change as assessed by the subject using the Bain & Findley ADL rating scale.
The Bain and Findley Activities of Daily Living (BF-ADL) assessment evaluates the subject's ability to perform a number of specific ADLs, measured before and after treatment. Each ADL is performed by the subject and self-rated on a scale of 1-4, with higher scores indicating greater difficulty in performing the task. |
Immediately before and after 40 minute stimulation session | |
Other | Change in Bain & Findley ADL: Inserting Plug Into Socket | The change in tremor severity on inserting a plug into a socket as assessed by the subject using the Bain & Findley ADL rating scale.
The Bain and Findley Activities of Daily Living (BF-ADL) assessment evaluates the subject's ability to perform a number of specific ADLs, measured before and after treatment. Each ADL is performed by the subject and self-rated on a scale of 1-4, with higher scores indicating greater difficulty in performing the task. |
Immediately before and after 40 minute stimulation session | |
Other | Change in Bain & Findley ADL: Unlocking | The change in tremor severity on unlocking a lock with a key as assessed by the subject using the Bain & Findley ADL rating scale.
The Bain and Findley Activities of Daily Living (BF-ADL) assessment evaluates the subject's ability to perform a number of specific ADLs, measured before and after treatment. Each ADL is performed by the subject and self-rated on a scale of 1-4, with higher scores indicating greater difficulty in performing the task. |
Immediately before and after 40 minute stimulation session | |
Primary | Change in TETRAS Spiral Rating After Stimulation | The primary effectiveness variable is the change in tremor severity immediately after the stimulation session compared to baseline (immediately prior to stimulation) as measured using the TETRAS Archimedes spiral task (assessed by 3 blinded raters).
The Essential Tremor Rating Assessment Scale (TETRAS) is a commonly used scale to assess and measure the severity of essential tremor. Each task was calculated individually on a 0-4 scale, with higher scores indicating more severe tremors. |
Immediately before and after 40 minute stimulation session | |
Secondary | Change in TETRAS Spiral Rating During Stimulation | An additional analysis variable is the change in tremor severity during the stimulation session (30 minutes into stimulation session) compared to baseline (immediately prior to stimulation) as measured using the TETRAS Archimedes spiral task (assessed by 3 blinded raters).
The Essential Tremor Rating Assessment Scale (TETRAS) is a commonly used scale to assess and measure the severity of essential tremor. Each task was calculated individually on a 0-4 scale, with higher scores indicating more severe tremors. |
Immediately before and 30 minutes into stimulation session | |
Secondary | Self-report Improvement | The percentage of subjects in the treatment group indicating improvement on the CGI-I Scale will be compared to the sham group. The Clinical Global Impression - Improvement (GGI-I) scale evaluates a clinician's rating of tremor improvement noted in the subject, as a result of the treatment. The scale ranges from 1 (very much improved) to 7 (very much worse). | Immediately before and after 40 minute stimulation session |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05381688 -
VIM DBS Respiratory Modulation: N-of-1 Trial
|
||
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Completed |
NCT02277106 -
Evaluate SAGE-547 in Participants With Essential Tremor
|
Phase 2 | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Terminated |
NCT02678429 -
Atlas Predicted DBS Settings in Essential Tremor
|
N/A | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A | |
Completed |
NCT02523807 -
Tremor Monitoring Device
|
N/A | |
Active, not recruiting |
NCT02255929 -
Gamma Knife Radiosurgery for Treatment of Essential Tremor
|
N/A | |
Completed |
NCT01223144 -
Decision-making and Emotion Recognition in Essential Tremor
|
N/A | |
Completed |
NCT00906412 -
Ventrointermediate Nucleus (VIM DBS) and Working Memory
|
N/A | |
Recruiting |
NCT05214222 -
Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT03051178 -
Wearable Sensor for Responsive DBS for ET
|
N/A | |
Recruiting |
NCT03795935 -
Relief From Side Effects: Clinical Use of Electrodes With Direction
|
N/A | |
Not yet recruiting |
NCT06036368 -
Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor
|
N/A | |
Recruiting |
NCT05897775 -
Coordinated Reset Deep Brain Stimulation for Essential Tremor
|
Phase 1 | |
Recruiting |
NCT05968976 -
Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET
|
N/A | |
Completed |
NCT06314139 -
Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study.
|
N/A | |
Recruiting |
NCT04501133 -
Sensory-specific Peripheral Stimulation for Tremor Management
|
N/A | |
Active, not recruiting |
NCT03560622 -
Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy
|
N/A | |
Completed |
NCT00368199 -
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
|
N/A |